Abstract:BACKGROUND:Though overexpression of epidermal growth factor receptor (EGFR) in several forms of cancer is considered to be an important prognostic biomarker related to poor prognosis, clear correlations between biomarker assays and patient management have been difficult to establish. Here, we utilize a targeting directly followed by a non-targeting tracer-based positron emission tomography (PET) method to examine some of the aspects of determining specific EGFR binding in tumors.METHODS:The EGFR-binding Affibody molecule ZEGFR:2377 and its size-matched non-binding control ZTaq:3638 were recombinantly fused with a C-terminal selenocysteine-containing Sel-tag (ZEGFR:2377-ST and ZTaq:3638-ST). The proteins were site-specifically labeled with DyLight488 for flow cytometry and ex vivo tissue analyses or with (11)C for in vivo PET studies. Kinetic scans with the (11)C-labeled proteins were performed in healthy mice and in mice bearing xenografts from human FaDu (squamous cell carcinoma) and A431 (epidermoid carcinoma) cell lines. Changes in tracer uptake in A431 xenografts over time were also monitored, followed by ex vivo proximity ligation assays (PLA) of EGFR expressions.RESULTS:Flow cytometry and ex vivo tissue analyses confirmed EGFR targeting by ZEGFR:2377-ST-DyLight488. [Methyl-(11)C]-labeled ZEGFR:2377-ST-CH3 and ZTaq:3638-ST-CH3 showed similar distributions in vivo, except for notably higher concentrations of the former in particularly the liver and the blood. [Methyl-(11)C]-ZEGFR:2377-ST-CH3 successfully visualized FaDu and A431 xenografts with moderate and high EGFR expression levels, respectively. However, in FaDu tumors, the non-specific uptake was large and sometimes equally large, illustrating the importance of proper controls. In the A431 group observed longitudinally, non-specific uptake remained at same level over the observation period. Specific uptake increased with tumor size, but changes varied widely over time in individual tumors. Total (membranous and cytoplasmic) EGFR in excised sections increased with tumor growth. There was no positive correlation between total EGFR and specific tracer uptake, which, since ZEGFR:2377 binds extracellularly and is slowly internalized, indicates a discordance between available membranous and total EGFR expression levels.CONCLUSIONS:Same-day in vivo dual tracer imaging enabled by the Sel-tag technology and (11)C-labeling provides a method to non-invasively monitor membrane-localized EGFR as well as factors affecting non-specific uptake of the PET ligand.

HaloTag as a Reporter Gene for Positron Emission Tomography

HaloTag: a novel reporter gene for positron emission tomography.

HaloTag As a Reporter Gene: Positron Emission Tomography Imaging with (64)Cu-Labeled Second Generation HaloTag Ligands.

Development of a Radiotracer for PET Imaging of the SNAP Tag.

One-step Radiosynthesis of 18F-Alf-nota-rgd2 for Tumor Angiogenesis PET Imaging

Engineered Antibody Fragments With Infinite Affinity As Reporter Genes For Pet Imaging

Positron Emission Tomography Imaging of Tumor Angiogenesis with a 66Ga-Labeled Monoclonal Antibody.

Site-specific π-clamp-mediated radiosynthesis of 68Ga and 18F PET radiopharmaceuticals

Positron Emission Tomography Imaging of Tumor Angiogenesis with a (61/64)Cu-Labeled F(ab')(2) Antibody Fragment.

Optical Imaging of Reporter Gene Expression Using a Positron-Emission-tomography Probe.

Evaluation of the Cytosolic Uptake of HaloTag Using a pH-Sensitive Dye

HER2-Positive Tumors Imaged Within 1 Hour Using a Site-Specifically 11C-Labeled Sel-Tagged Affibody Molecule

Molecular Imaging and Pharmacokinetics of (99m) Tc-hTERT Antisense Oligonucleotide As a Potential Tumor Imaging Probe.

An Engineered Cysteine-Modified Diabody for Imaging Activated Leukocyte Cell Adhesion Molecule (ALCAM)-Positive Tumors

Syntheses and Preliminary Evaluation of [18f]alf‐nota‐g‐tmtp1 for PET Imaging of High Aggressive Hepatocellular Carcinoma

Positron Emission Tomography Imaging of CD105 Expression with a 64Cu-Labeled Monoclonal Antibody: NOTA is Superior to DOTA

Preclinical PET Imaging of EGFR Levels: Pairing a Targeting with a Non-Targeting Sel-tagged Affibody-based Tracer to Estimate the Specific Uptake

Mechanism-Based Strategy for Optimizing HaloTag Protein Labeling

Preclinical Evaluation of [68Ga]ga-Malat-1-antisense Oligonucleotides for Specific PET Imaging of MALAT-1 Expressing Tumours

Development of a new positron emission tomography tracer for targeting tumor angiogenesis: synthesis, small animal imaging, and radiation dosimetry

Biological Evaluation of [18F]AlF-NOTA-NSC-GLU as a Positron Emission Tomography Tracer for Hepatocellular Carcinoma